Chile Tecnovigilancia Reporting Deadlines: Sentinel, Adverse Event and Trend Tiers

Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20

1. Key takeaways

The ISP consultation draft of the National Tecnovigilancia System Guide sets three tiers of reporting deadlines: sentinel events (evento centinela) must be reported immediately and no later than 2 working days; adverse events within 10 working days; adverse events with an increased occurrence rate within 20 working days after the trend has been confirmed. Investigation responses are suggested to be filed in stages at 20, 40 and 60 working days for the initial, interim and final reports respectively.

These three tiers remain proposed requirements as of October 29, 2026 — the guide is a consultation draft — and current duties continue to run under the Norma General Técnica N° 204 system. GRZAN’s recommendation is to design internal procedures around the proposed deadlines, so that when the final text takes effect the changeover is a switch, not a rebuild. The deadlines are short enough that a company that waits for final publication will not be able to recruit, train and template its way into compliance in time; the 2-working-day tier in particular leaves essentially no room for improvisation. The classification decision — whether an event is a sentinel event, a single adverse event, or part of a rising trend — determines which clock starts, and that decision must therefore be made quickly and by someone competent to make it.

2. Legal basis

  • ISP public consultation | National Tecnovigilancia System Guide | launched August 27, 2026, consultation period until September 27, 2026 | Reporting deadlines: sentinel events immediately and no later than 2 working days; adverse events 10 working days; adverse events with an increased occurrence rate 20 working days after the trend is confirmed; investigation responses suggested at 20 / 40 / 60 working days for the initial, interim and final reports respectively.
  • Current system | Norma General Técnica N° 204 | issued December 21, 2018 | requires healthcare providers to report incidents and adverse events, prioritizing adverse events and sentinel events involving critical medical equipment.
  • Regulation on the control of pharmaceutical products and medical devices | Decreto Supremo N° 825, de 1998 | August 21, 1999 | Article 28: post-market reporting obligations.
  • ISP forms | ANDID/006 (device adverse events) and ANDID/010 (IVD adverse events) | submitted through the integrated vigilance system.

3. Expert insights

Insight one: the three deadline tiers correspond to three different kinds of risk signal.

Sentinel events are the most severe signal — typically events that were avoidable yet resulted in death or serious harm — so they carry the shortest deadline. Adverse events are the routine signal and sit in the middle tier. Adverse events with an increased occurrence rate are a trend signal: the trend must first be confirmed before the clock in that tier is engaged, which is why the deadline is the longest. The accuracy of the classification decision directly determines whether the starting point of the deadline is correct. Misclassifying a rising trend as a single adverse event is not a minor paperwork error; it restarts the analysis under the wrong clock and can leave the company reporting late even though it acted in good faith.

Insight two: immediately and no later than 2 working days is the harshest tier.

2 working days means there is almost no internal review time between becoming aware of the event and submitting the report. GRZAN’s approach is to define a sentinel-event assessment checklist in advance, so that front-line staff can identify the event and trigger the report without escalating through levels of management first. The checklist converts a judgement call into a structured decision that can be made in hours, and it protects the deadline even when the responsible person is travelling or unavailable.

Insight three: investigation responses are filed in stages at 20 / 40 / 60 working days.

The guide suggests initial, interim and final reports at 20, 40 and 60 working days respectively. This is a progress-management requirement, not a come back after 60 days permission — the initial report is due within the first 20 working days whether or not the investigation is finished. Companies that treat the final deadline as the only real one routinely miss the first checkpoint and create the impression of an unmanaged investigation.

Insight four: the starting point is awareness, not confirmation.

Reporting deadlines are generally calculated from the day the company becomes aware of the event (practical estimate; the final text governs). This means waiting for the investigation results before reporting is the wrong approach: the correct practice is to report within the deadline first and supplement as the investigation progresses. Building the event ledger on the awareness date, rather than on the confirmation date, is what keeps the timelines honest and auditable.

4. Practical recommendations

  1. Define the sentinel-event assessment checklist in advance so front-line staff can identify qualifying events directly and trigger reporting without managerial escalation.
  2. Build a countdown schedule for the three deadline tiers: 2 working days (sentinel), 10 working days (adverse events), 20 working days (trend signals), each anchored to the awareness date recorded in the event ledger.
  3. Place investigation response milestones at 20 / 40 / 60 working days; the initial report is never optional and must be drafted against a template before any event occurs.
  4. Anchor the event ledger to the awareness date, not the confirmation date, and record how the awareness date was established so the timeline can be reconstructed later.
  5. State information return deadlines in distribution agreements, ensuring the Chilean side learns of events early enough to meet the shortest tiers.

5. Verification checklist

  • □ Confirmed that the three deadline tiers are proposed requirements and current duties run under Norma N° 204
  • □ A sentinel-event assessment checklist has been defined in advance
  • □ A countdown schedule for 2 / 10 / 20 working days exists
  • □ Investigation response milestones are placed at 20 / 40 / 60 working days
  • □ The event ledger uses the awareness date as its starting point

Regulatory information verified as of October 29, 2026.

GRZAN supports manufacturers, importers and authorised representatives with post-market compliance in Chile, including tecnovigilancia reporting, FSCA and recall execution, record-keeping systems and SEREMI inspection response. For a product-specific feasibility assessment or post-market compliance support for the Chilean market, contact the GRZAN regulatory team at info@grzanglobal.com.

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail